Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. Issue 200 (June 2020)

• Record Type: Journal Article
• Authors: Bahrami, Nazli; Chang, Gregory; Kanaya, Noriko; Sauer, Torill; Park, Daehoon; Loeng, Marie; Gravdehaug, Berit; Chen, Shiuan; Geisler, Jürgen
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 200(2020)
• Publication Date: 2020-06
• Subjects: Aromatase inhibitor -- Letrozole -- Exemestane -- Androgens -- Estrogens -- Breast cancer; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2020.105641
• Languages: English
• ISSNs: 0960-0760

Abstract

Highlights: Letrozole and exemestane are established aromatase inhibitors. A lack of cross-resistance has been observed between these compounds. The AroER tri-screen assay was used to evaluate estrogenic activity in serum samples. Letrozole causes lower serum estrogenic activity compared to exemestane. Abstract: The aromatase inhibitors (AIs), letrozole (Femar®/Femara®) and exemestane (Aromasin®), are widely used to treat estrogen receptor (ER) positive breast cancer in postmenopausal patients. In the setting of metastatic breast cancer, these drugs may be used after another causing new responses in selected patients after progressing on the first choice. The precise explanation for this "lack of cross resistance" is still missing. NEOLETEXE is a neoadjuvant, randomized, open-label, cross-over trial. Postmenopausal patients with ER-positive, HER-2 negative, locally advanced breast cancer were enrolled. All patients were randomized to treatment starting with either letrozole or exemestane for at least 2 months followed by another 2 months on the alternative AI. The total estrogenic activities in blood samples were determined using the AroER tri-screen assay developed in the Chen laboratory. Using this highly sensitive assay, estrogenic activity was detected at three time points for all patients. Importantly, a significantly higher total estrogenic activity was found during therapy with exemestane compared to letrozole in 21 out of 26 patients. When letrozole was included in the AroER tri-screen assay, the estrogenic activities in most samples collected during exemestane treatment were further reduced, suggesting that low levels of androgens remained in specimens obtained after exemestane treatment. Our results suggest the AroER tri-screen to be a very sensitive method to estimate the overall estrogen-mediated activity in human samples even during therapy with highly potent aromatase inhibitors. In the present study, serum estrogen activity was significantly higher during exemestane therapy when compared to letrozole therapy.